Sentiment Summary
Recent Events
Ex-dividend date (2026-06-24) for the proposed final dividend of HKD 0.15 per share for the fiscal year 2025, scheduled.
Ex-dividend date for final dividend of HK$0.05 per share for the year ended December 31, 2025, scheduled for 2026-06-24. Dividend adjustment typically results in a ~1% price impact, scheduled.
Pfizer is scheduled to report its Q1 2026 earnings on May 5, 2026. Analysts forecast EPS of $0.74 and revenue of $13.9 billion. Market impact is estimated at Medium (5%) as earnings reports typically drive significant volatility. This release is scheduled.
Vertex first quarter 2026 financial results announcement after market close on May 4, 2026, scheduled. Impact is estimated as neutral as the market awaits actual performance data.
Amgen is scheduled to report its Q1 2026 financial results after the market closes on April 30, 2026, scheduled. Earnings reports for major pharmaceutical companies typically result in price movements exceeding 5%.
Bristol-Myers Squibb is scheduled to announce its Q1 2026 financial results on April 30, 2026, before the market opens, followed by a conference call with the investment community; a Medium importance is estimated as earnings releases typically impact stock prices by at least 5%, scheduled.
Q1 2026 earnings release is scheduled. A medium impact is estimated as earnings reports typically drive significant price movement.
Merck is scheduled to announce its Q1 2026 financial results and hold a conference call with investors and analysts on April 30, 2026; analysts estimate a price impact of at least 5%, estimated.
AbbVie is scheduled to announce its first-quarter 2026 financial results on April 29, 2026; medium importance as quarterly results are estimated to have a price impact of 5% or more scheduled
Estimated low impact (<5%) as the date announcement is routine; first quarter 2026 earnings results are scheduled.
Board meeting to approve and publish the first quarter 2026 financial results; market impact is estimated at ~5% as quarterly results often drive significant price volatility, expected.
Q1 2026 earnings release scheduled for 2026-04-21. Analysts forecast EPS of approximately $1.94 forecasted. Medium importance as earnings releases typically trigger significant price movement scheduled.
Presentation of new and updated data from several studies, including preclinical data for HMPL-A580 (a first-in-class ATTC), at the American Association of Cancer Research (AACR) Annual Meeting from April 17-22, 2026, is scheduled.
Abbott is scheduled to announce its Q1 2026 financial results on April 16, 2026, before the market opens; analysts forecast EPS of $1.15 and revenue of $11.0 billion; earnings releases typically result in a ~5% price impact scheduled.
RemeGen announced on April 15, 2026, the receipt of a US$650 million upfront payment from AbbVie for the exclusive licensing of RC148; High importance estimated due to the massive cash infusion likely resulting in >10% price impact.
Kimberly-Clark announced the post-closing organizational structure and key leadership for the company following its pending acquisition of Kenvue on 2026-04-15.
The company's antibody-drug conjugate, SYS6051, received approval from China's National Medical Products Administration (NMPA) to start clinical trials for treating advanced solid tumors.
Announced that its subsidiary received approval from China's National Medical Products Administration (NMPA) for the clinical trial of HRS-7156 tablets, a self-developed Class 1 new drug for heart failure. Market impact is estimated at ~1% as clinical trial approvals for early-stage drugs typically have limited immediate price impact.
The ex-dividend date for AbbVie's quarterly cash dividend of $1.73 is scheduled for April 15, 2026; low importance as the dividend event is estimated to have a price impact of 1% or more scheduled
Announced that its associate, Legend Biotech, recorded approximately US$597 million in net trade sales for its CAR-T therapy, CARVYKTI®, for the quarter ended March 31, 2026, a year-over-year increase of 61.8%. Analysts estimate a 5-10% price impact due to significant growth in core product sales, estimated.
Announced positive results from a Phase II study of sacituzumab tirumotecan (sac-TMT) in combination with pembrolizumab for gynecologic cancers, presented at the 2026 SGO Annual Meeting. The data showed promising efficacy and a manageable safety profile.
The "-B" marker was removed from the company's stock code on the Hong Kong Stock Exchange, effective April 14, 2026. This signifies the company has met the exchange's main board revenue and market capitalization requirements for established companies.
Johnson & Johnson reported Q1 2026 sales of $24.1 billion and adjusted EPS of $2.70, beating analyst estimates, and raised its full-year guidance with a 3.1% dividend increase. Estimated 5% impact due to strong earnings and guidance; expected.
On April 14, 2026, it was reported that the US FDA refused to file partner Replimune's application for its drug RP1 in combination with Bristol Myers Squibb's Opdivo for advanced melanoma, citing concerns about the study design.
The Board of Directors announced its approval for a proposed IPO on the Shanghai Stock Exchange's STAR Market on April 13, 2026, aiming to raise up to RMB 6.75 billion. A shareholder meeting to approve the plan is scheduled for April 29, 2026. This event is estimated to have a >=10% price impact due to the scale of the capital raise and potential for valuation re-rating, scheduled.
AbbVie is scheduled to announce an exclusive licensing agreement with Haisco Pharmaceutical for Nav1.8 inhibitors on April 13, 2026; medium importance as the deal is estimated to have a price impact of 5% or more scheduled
Announced positive results from the Phase 3 BRUIN CLL-322 trial, where Jaypirca in combination with venetoclax and rituximab significantly improved progression-free survival in patients with previously treated chronic lymphocytic leukemia (CLL).
The U.S. FDA is expected to accept and grant Priority Review for the Biologics License Application for ifinatamab deruxtecan on April 13, 2026, with a decision date set for October 10, 2026; analysts estimate a price impact of at least 5%, estimated.
On April 12, 2026, partner GSK presented highly positive Phase 1b clinical trial results for mocertatug rezetecan (HS-20093), an antibody-drug conjugate licensed from Hansoh, showing a 62% overall response rate in platinum-resistant ovarian cancer and 67% in endometrial cancer. GSK plans to advance to five Phase 3 trials.
AbbVie is scheduled to present Phase 2 data for ELAHERE® at the SGO Annual Meeting on April 12, 2026; low importance as the data presentation is estimated to have a price impact of 1% or more scheduled
On April 10, 2026, RemeGen announced that China's NMPA approved the new drug application for Disitamab Vedotin (RC48); Medium importance estimated as core product approval typically drives a 5-10% market reaction.
Announced that its subsidiary received approval from China's NMPA for the clinical trial of HRS-5765 tablets, a self-developed Class 1 new drug for heart failure. Market impact is estimated at ~1% as clinical trial approvals for early-stage drugs typically have limited immediate price impact.